




SEA-BCMA

An investigational sugar-engineered antibody directed to B cell maturation agent (BCMA)



Key Attributes

- Humanized, nonfucosylated IgG1 monoclonal antibody¹
- Increased affinity for activating FcγRIIIa and minimal affinity for inhibitory FcγRIIb^{1,2}
- Binding to FcγRIIIa confers enhanced Fc-mediated effector function^{1,2}

Target: BCMA

- A cell surface receptor found on plasma cells, essential for long-term survival¹⁻³
- Mediates pro-survival and proliferative cell signaling by binding APRIL and BAFF^{2,3}
- Universally expressed in malignant plasma cells^{3,4}
- Limited expression in nonhematopoietic cells^{3,4}

Proposed Mechanism of Action^{5,a}

- Enhanced antibody-dependent cellular cytotoxicity
- Antibody-dependent cellular phagocytosis
- Blockade of BCMA-mediated pro-survival and proliferative signaling in malignant plasma cells

APRIL: A proliferation-inducing ligand; **BAFF:** B lymphocyte-activating factor of the tumor necrosis factor family; **BCMA:** B-cell maturation antigen; **IgG1:** immunoglobulin G1

^a Based on preclinical data.


1. Abdallah AA, et al. *J Clin Oncol*. 2019;37(Suppl 15):TPS8054. 2. Van Epps H, et al. *Cancer Res*. 2018;78(Suppl 13):Abstract 3833. 3. Novak AJ, et al. *Blood*. 2004;103(2):689-694. 4. Seckinger A, et al. *Cancer Cell*. 2017;31(3):396-410. 5. Van Epps H, et al. Abstract presented at: AACR; Apr 2018; Chicago, IL. Abstract 7503.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Proposed Mechanism of Action^{1,2,a}

- 1 Blocks APRIL and BAFF ligand binding
- 2 Mediates antibody-dependent cellular phagocytosis
- 3 Displays enhanced antibody-dependent cellular cytotoxicity



APRIL: A proliferation-inducing ligand; **BAFF:** B lymphocyte-activating factor of the tumor necrosis factor family; **NK:** natural killer

^a Proposed mechanisms of action based on preclinical data are currently under investigation.

1. Van Epps H, et al. Abstract presented at: AACR; Apr 2018; Chicago, IL. Abstract 7503.

Clinical Trials



RECRUITING

SGNBCMA-001: Relapsed/refractory multiple myeloma (NCT03582033) SEA-BCMA

Phase 1

Phase 2

Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed October 2022.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.